Thirty Years of GCP: The Evolution From Study Execution to Evidence Generation

Ask any clinical research professional what Good Clinical Practice (GCP) has achieved over the past 30 years, and the answers are likely to be remarkably consistent.

Participant protection has improved. Regulatory expectations have become more harmonized. Data integrity standards have strengthened. Global clinical development has become possible on a scale that would have been difficult to imagine when ICH E6 was first introduced in 1996.

All of these achievements matter, yet for sponsors investing millions in evidence generation, a more provocative question deserves attention. Have 30 years of increasingly sophisticated clinical operations translated into 30 years of better clinical evidence?

The answer may be the industry’s biggest elephant in the room - everyone senses it, few discuss it openly, and even fewer are willing to challenge it.

Although clinical research has become exceptionally good at managing studies, it continues to face challenges in designing studies that consistently generate decisive evidence. Recruitment delays remain common. Placebo effects continue to surprise experienced development teams. Promising products occasionally fail not because they lack efficacy, but because the study population, end points, or operational assumptions were not aligned with the underlying biological hypothesis.

Thirty years after GCP transformed how studies are conducted, the industry’s next challenge may be improving how studies are conceived.

The Problem GCP Was Designed to Solve

To appreciate where the industry is heading, it is worth remembering the environment in which GCP was born.

• The original objective of GCP was not to improve recruitment efficiency, optimize end points, or accelerate development timelines. It was to establish trust.
• Trust that participants would be protected.
• Trust that investigators would conduct research ethically.
• Trust that regulators reviewing a submission in one geography could rely on data generated in another.

In that respect, GCP has been one of the most successful regulatory frameworks in modern health care. It created a common language for sponsors, investigators, clinical research organizations (CROs), ethics committees, and regulators across the world. Few would argue that clinical research today is safer, more transparent, and more globally integrated than it was 3 decades ago.

But success often creates new expectations. As the industry matured, sponsors began asking questions that GCP was never specifically designed to answer.

• Can we identify the right participants before recruitment begins?
• Can protocol risks be anticipated before they become operational problems?
• Can studies be designed to reduce variability rather than merely measure it?
• Can evidence generation become more predictable?

These questions sit beyond traditional compliance. Increasingly, they sit at the center of business strategy.

When Compliance Became a Commodity

For many years, operational excellence has been the dominant differentiator in clinical research. Organizations invested heavily in monitoring, quality systems, documentation practices, and audit readiness. CROs built capabilities around execution. Sponsors focused on timelines, site activation metrics, and database lock dates.

These investments were necessary and valuable. However, something interesting happened along the way. Operational competence gradually became an expectation rather than a differentiator.

Today, sponsors assume that a qualified CRO can conduct monitoring visits, manage study documentation, and navigate regulatory requirements. These capabilities remain essential, but they are no longer enough to create strategic value.

The conversation in executive boardrooms has evolved. The question is no longer, “Can this study be executed?” The question is increasingly, “Will this study generate evidence strong enough to support a meaningful decision?”

That distinction is reshaping the clinical research landscape.

The Costliest Failures Rarely Appear in Audit Reports

One of the great paradoxes of modern clinical research is that some of the most expensive failures occur in studies that are technically well executed.

A study can be inspection-ready, fully compliant, and operationally successful while still failing to produce commercially meaningful evidence.

The reasons are familiar to experienced development teams.

• The study population may be too heterogeneous.
• The end point may not adequately capture product differentiation.
• The placebo response may be underestimated.
• Recruitment assumptions may prove unrealistic.
• The protocol may inadvertently introduce variability that obscures the treatment effect.

None of these challenges is typically identified through routine monitoring activities. Most originate much earlier, during study design.

This reality is driving a growing appreciation for protocol derisking, feasibility intelligence, and quality-by-design approaches that seek to identify scientific and operational vulnerabilities before the first participant is enrolled.

Increasingly, the industry’s most valuable quality intervention occurs long before monitoring begins.

COVID-19 Did More Than Accelerate Digitalization

The COVID-19 pandemic is often described as the catalyst that accelerated decentralized clinical trials (DCT), remote monitoring, telemedicine, and digital health technologies. That interpretation is correct, but incomplete. The pandemic also challenged one of the industry’s long-standing assumptions that quality is best maintained through physical oversight.

Faced with unprecedented disruption, sponsors and regulators were forced to focus on participant safety, data reliability and study continuity. Many traditional processes were adapted, modified, or replaced. Yet the core principles of GCP remained intact.

The experience revealed an important lesson. Quality is not defined by the location of a monitoring visit, the thickness of a trial master file, or the number of source documents reviewed. Quality is defined by whether a study generates trustworthy evidence while protecting participants.

This lesson continues to influence how modern studies are designed and managed.

ICH E6(R3): More Than Just Another Revision

At first glance, ICH E6(R3) appears to be another regulatory update. In reality, it signals something much bigger.

For years, the industry has been moving toward risk-based oversight, quality-by-design, and a greater focus on the factors that truly determine study success. E6(R3) does not introduce these ideas; it acknowledges that they are now central to how modern clinical research is conducted.

The shift is subtle but important. Traditional approaches often treated quality as an activity that could be verified through monitoring, documentation, and inspection. The revised guideline places greater emphasis on building quality into the study from the outset through thoughtful protocol design, precise participant selection, proactive risk assessment, and a clear understanding of what is critical to participant safety and data reliability.

In many ways, E6(R3) formalizes a reality that forward-looking sponsors and CROs have already begun to embrace: not every risk deserves the same attention, and not every process contributes equally to study quality.

That change in thinking may prove to be far more important than any individual update within the guideline itself.

The Emergence of Evidence Engineering

Perhaps the most important development in modern clinical research is one that receives relatively little attention. Sponsors are increasingly recognizing that evidence generation itself can be optimized.

Historically, clinical development focused heavily on operational execution after protocol approval. Today, more attention is being directed toward the decisions that occur before recruitment begins.

• Which participants should be recruited?
• Which end points are most likely to demonstrate meaningful benefit?
• How can biological variability be reduced?
• Which operational assumptions represent the greatest threat to study success?
• Can responder populations be identified more effectively?
• Can adaptive strategies improve study efficiency without compromising rigor?

These questions are giving rise to what might best be described as evidence engineering—a deliberate effort to improve the probability that a study will generate meaningful, decision-enabling outcomes.

The implications extend far beyond efficiency. They influence scientific credibility, regulatory confidence, commercial differentiation, and ultimately return on investment.

Why Sponsors Are Redefining the Role of CROs

As evidence generation becomes more strategic, expectations of CROs are evolving as well. The traditional CRO model was built around execution. The emerging model is increasingly centered on partnership.

Sponsors are seeking organizations capable of contributing insight before protocols are finalized, helping identify potential vulnerabilities before they become costly realities.

This includes deeper involvement in study design, recruitment strategy, end point selection, operational risk assessment, participant engagement, and emerging approaches such as phenotype-informed recruitment and responder enrichment.

The shift is subtle but significant.

Sponsors are no longer looking solely for organizations that can run studies efficiently. They are looking for partners that can improve the likelihood that a study succeeds. That expectation is changing the definition of value across the CRO industry.

The Next Competitive Advantage Will Not Be Technology Alone

Artificial intelligence, digital biomarkers, wearable technologies, real-world evidence platforms, and advanced data analytics will undoubtedly influence the future of clinical research.

But technology alone rarely creates lasting competitive advantage. The organizations that benefit most from these innovations will be those that use them to answer better questions, design better studies, and generate better evidence.

The future belongs not to those who collect the most data, but to those who generate the most meaningful insights from it. In that sense, the next evolution of clinical research is unlikely to be purely digital. It will be intellectual.

Looking Beyond Compliance

Thirty years after the introduction of GCP, compliance is no longer the industry’s defining challenge. Most organizations have robust quality systems, established processes, and the operational expertise needed to conduct studies in accordance with regulatory expectations.

What increasingly differentiates successful development programs is not how efficiently a study is executed, but how effectively it is designed.

As products become more specialized, end points more demanding, and development decisions more consequential, greater attention is being directed toward the choices made long before the first participant is enrolled. Study populations, end point selection, protocol feasibility, operational risks, and participant experience are all emerging as critical determinants of success.

GCP established the foundation upon which modern clinical research was built. The next phase of the industry’s evolution will be shaped by its ability to generate evidence that is not only credible and compliant, but also meaningful, decision-enabling, and fit for an increasingly competitive health care landscape.

Ultimately, the organizations that create the greatest value will not necessarily be those that run studies better. They will be those who design better studies in the first place.